Abstract
Metastatic malignant melanoma remains a highly aggressive form of skin cancer for which no reliable methods for treatment exist. Given the increasing incidence of this cancer, considerable attention has focused on the development of new and improved methods for tackling this disease. Within this article, methods for treating melanoma are reviewed and discussed with particular attention focusing on prodrugs that are activated by the tyrosinase enzyme. This enzyme is up-regulated and is of elevated activity within malignant melanomas compared with healthy melanocytes, providing an ideal in-situ tool for the activation of melanoma prodrugs. By way of background to the prodrug strategies discussed within this review, the causes of melanoma, the enzymology of tyrosinase, and the chemistry of the biosynthetic pathways associated with melanogenesis are presented. Aspects of the design, mode of action, and biological profiles of key prodrugs that are activated by tyrosinase, and that show potential for the treatment of melanoma, are then presented and compared.
Keywords: Melanoma, prodrug, tyrosinase, ortho, melanogenesis, metastasis
Anti-Cancer Agents in Medicinal Chemistry
Title: Tyrosinase Activated Melanoma Prodrugs
Volume: 9 Issue: 7
Author(s): Samaila Jawaid, Tariq H. Khan, Helen M.I. Osborn and Nana Aba O. Williams
Affiliation:
Keywords: Melanoma, prodrug, tyrosinase, ortho, melanogenesis, metastasis
Abstract: Metastatic malignant melanoma remains a highly aggressive form of skin cancer for which no reliable methods for treatment exist. Given the increasing incidence of this cancer, considerable attention has focused on the development of new and improved methods for tackling this disease. Within this article, methods for treating melanoma are reviewed and discussed with particular attention focusing on prodrugs that are activated by the tyrosinase enzyme. This enzyme is up-regulated and is of elevated activity within malignant melanomas compared with healthy melanocytes, providing an ideal in-situ tool for the activation of melanoma prodrugs. By way of background to the prodrug strategies discussed within this review, the causes of melanoma, the enzymology of tyrosinase, and the chemistry of the biosynthetic pathways associated with melanogenesis are presented. Aspects of the design, mode of action, and biological profiles of key prodrugs that are activated by tyrosinase, and that show potential for the treatment of melanoma, are then presented and compared.
Export Options
About this article
Cite this article as:
Jawaid Samaila, Khan H. Tariq, Osborn M.I. Helen and Williams Aba O. Nana, Tyrosinase Activated Melanoma Prodrugs, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/187152009789056886
DOI https://dx.doi.org/10.2174/187152009789056886 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents
Current Cancer Therapy Reviews Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Apoptosis and Apoptosis-Based Therapy in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry miR-203 Suppresses the Proliferation and Metastasis of Hepatocellular Carcinoma by Targeting Oncogene ADAM9 and Oncogenic Long Non-coding RNA HULC
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews A Review of Surgical Options to Preserve Fertility in the Treatment of Early Cervical Cancer
Current Women`s Health Reviews Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry Treatment of Atopic Dermatitis: Current Status and Future Prospects
Current Drug Therapy New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Breast Reconstruction – A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy
Current Cancer Therapy Reviews Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Anti-Cancer Agents in Medicinal Chemistry Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences